HCL and UNLEASH Partner to Develop Solutions for Aquatic Ecosystem Conservation
20.5.2022 18:59:00 EEST | Business Wire | Press release
HCL Group and UNLEASH, a global innovation program for the UN Sustainable Development Goals (SDGs), announced a year-long collaboration to mobilize youth and develop innovative solutions to promote aquatic ecosystem conservation. These solutions will aim to tackle challenges from Source (mountains & glaciers) to Sink (oceans and seas) and their links to terrestrial ecosystems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220520005178/en/
Nature and ocean conservation play a critical role in our survival. Terrestrial and aquatic ecosystems provide us with food, water, oxygen, energy, and medicines. They regulate our climate, provide pollination to crops, and reduce the impact of natural hazards.
Despite the vital importance of our planet’s ecosystems, we are experiencing a human-caused deterioration of our natural habitats: human activity has altered almost 75% of the Earth’s terrestrial surface, squeezing wildlife and nature into an ever-smaller corner.1 Furthermore, ocean heat is at record levels and every year up to 12 million metric tonnes of plastic enter the ocean, damaging ecosystems around the world. Without maintaining healthy and biodiverse terrestrial and aquatic ecosystems, the progress on the remaining United Nations’ SDGs is at critical risk.
To tackle such challenges, UNLEASH and HCL will collaborate to establish a year of youth-led action. Specifically, the partnership will allow youth to develop solutions encompassing SDG 14 (Life below water) and SDG 15 (Life on land), and explore synergies with other SDGs as well. During the process, they will be guided by industry experts and receive hands-on support to ensure that solutions are relatable to the context and feasible in practice.
HCL Group with its large presence in business through HCL Technologies, HCL Infosystems and HCL Healthcare; and its social development organizations including the philanthropic Shiv Nadar Foundation and The Habitats Trust, and its CSR arm – HCL Foundation, has been tackling real on-ground issues related to the SDGs. The Group with its breadth of experience across different sectors and its holistic and powerful sustainability charter is the perfect partner for UNLEASH to successfully push its SDGs innovation efforts.
“Innovation, entrepreneurship, humanity and a people-centric culture are part of HCL’s core, and it is important to us that our progress is reflected in the development of a better world. Our various entities have already been driving important projects to help create a positive impact for the people and the planet. HCL’s collaboration with UNLEASH in bringing innovation to the SDGs, and specifically to the preservation of nature and ocean conservation is an essential step in our overall sustainability efforts”, said Roshni Nadar Malhotra, CEO of HCL, Chairperson of HCL Technologies, Trustee of Shiv Nadar Foundation & Founder of The Habitats Trust.
With HCL’s continuous support on the thematic track From Source to Sink, UNLEASH Talents will have the opportunity to work on localized challenges through joining an UNLEASH Hack at the Shiv Nadar University, Delhi NCR (part of the HCL Group). Earlier this year, UNLEASH Talents participated in three other UNLEASH Hacks related to this theme, exploring challenges of water ecosystems from the Mediterranean, the Danube, Haiti and Hawaii and defining solutions that can drive positive local impact on those regions. The partnership will help scale an existing early-stage solution in the biodiversity space through enrolment in an incubation program, UNLEASH Plus. Thematic insight sessions will be organized throughout 2022, providing inspiration and key learnings on the essence of the theme. These year-long efforts will culminate in the Global Innovation Lab in India that will witness a gathering of 1000+ talented youth for a week long innovation process and help them develop solutions for Indian and global challenges within aquatic and terrestrial ecosystem conservation. The best solutions from the Lab will take home grant prizes to kick-start implementation of the developed solutions. Through the course of this partnership, HCL will enable access to its celebrated business leaders, technical experts, and faculty and academicians of global repute to serve as facilitators, mentors and experts that will help participants across the various programs to develop innovative solutions.
The partnership enables UNLEASH to dive deep into SDG14 and SDG15, and truly establish a community of changemakers, working with nature challenges.
“HCL’s journey in innovation and development is an inspiration for the entire UNLEASH Community. We are very grateful for their partnership on an important matter such as the aquatic conservation of our planet and finding solutions for its preservation through our different programs during the course of this year”, said UNLEASH Chairman Flemming Besenbacher.
About HCL Group
Founded in 1976 as one of India’s original IT garage start-ups, HCL is a pioneer of modern computing with many firsts to its credit, including the introduction of the 8-bit microprocessor-based computer in 1978 well before its global peers. Today, the HCL Group has business presence across sectors including technology and healthcare and comprises three group companies –HCL Technologies, HCL Infosystems and HCL Healthcare. The Group generates annual revenues of over US$11.5 billion with more than 209,000 employees operating across 52 countries.
The Group also includes one of India’s most prolific philanthropic foundations – the Shiv Nadar Foundation. Established in 1994, the Foundation is committed to the creation of a more equitable, merit-based society by empowering individuals through transformational education. Over the last 27 years, it has invested over US$1billion in seven landmark institutions and initiatives across education and art. The Habitats Trust, also a philanthropic Foundation within the HCL Group, specifically works towards protecting natural habitats and their indigenous species of flora and fauna. Established in 2018, the young foundation is undertaking important initiatives that will help secure a positive future for wild species and their habitats.
HCL Foundation, the Corporate Social Responsibility arm of HCL, has instituted flagship programs and initiatives to contribute towards SDGs. Its work is helping bring about lasting positive impact on the people and planet, through long-term sustainable programs, and ensure equitable access, opportunities, and holistic development for all.
For further information, visit www.hcl.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220520005178/en/
Contact information
For any queries or information, please contact:
Sadaf Khan | Sadaf-k@hcl.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 11:15:00 EEST | Press release
Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easier to access, navigate and manage. This will ultimately give pet parents better guidance, greater confidence and more control at every point in
Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
